Pomerantz Law Firm Proceeds with Class Action Against Sarepta Therapeutics Over Investment Losses

Investor Alert: Class Action Against Sarepta Therapeutics

Pomerantz LLP has recently initiated a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT), particularly aimed at investors who experienced financial losses. Investors are strongly encouraged to connect with Pomerantz LLP by contacting Danielle Peyton at [email protected] or by calling 646-581-9980, toll-free at 888.4-POMLAW, Ext. 7980. Please include relevant details such as your mailing address, phone number, and the number of shares purchased via email inquiries.

Overview of the Case

This class action centers on allegations that Sarepta and certain members of its executive team engaged in securities fraud and other unlawful business practices. Investors who purchased shares during the defined Class Period must act quickly: the deadline to request to be appointed as Lead Plaintiff is August 25, 2025.

For those interested, a copy of the Complaint is readily available at the Pomerantz law firm’s website, www.pomerantzlaw.com.

Recent Developments Impacting Sarepta's Stock

The turmoil surrounding Sarepta began on March 18, 2025, when the company revealed the tragic death of a young man suffering from Duchenne muscular dystrophy after treatment with its drug, ELEVIDYS, due to acute liver failure. In reaction to this devastating news, Sarepta’s stock value plummeted by $27.81, approximately 27.44%, bringing the share price down to $73.54.

The situation escalated when, on April 4, 2025, Sarepta announced that European authorities prompted an independent data monitoring committee to review this death. During this period, recruitment and dosing in some ELEVIDYS clinical trials were halted, resulting in a further decrease of $4.18, or 7.13%, in share price, bringing it down to $54.43.

Adding to the distress, on June 15, 2025, another fatality associated with ELEVIDYS was disclosed, prompting Sarepta to suspend ongoing trials and limit distribution of the drug to non-ambulatory patients. This grim announcement caused an alarming drop of $15.24, or 42.12%, with shares closing at $20.94 on June 16.

In a Safety Communication released on June 24, the U.S. Food and Drug Administration (FDA) alerted stakeholders about investigating the risk of acute liver failure linked to ELEVIDYS treatments. This additional scrutiny led to another decline of $1.52, with shares settling at $17.46 on June 25.

Pomerantz LLP: A Leader in Class Action Litigation

Pomerantz LLP stands out as a preeminent law firm in corporate, securities, and antitrust class litigation. Established over 85 years ago by Abraham L. Pomerantz, the firm has built a reputation for championing the rights of victims in securities fraud and corporate misconduct cases. Their longstanding history includes recovering numerous multimillion-dollar settlements for impacted investors, showcasing their unwavering commitment to justice in the financial sector.

Investors who believe they may have been affected by the actions of Sarepta are urged to act swiftly, as the upcoming deadlines are critical for their involvement in litigation. The firm continues its tradition of providing robust legal representation to ensure victims of financial misconduct can seek the accountability they deserve.

For more information on how to join the class action or to learn about the steps involved, visit Pomerantz Law Firm. Time is of the essence for those who wish to participate in bringing accountability to Sarepta Therapeutics and its business practices.